Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R.
Nouri M, et al. Among authors: hollier bg.
Oncotarget. 2017 Mar 21;8(12):18949-18967. doi: 10.18632/oncotarget.14850.
Oncotarget. 2017.
PMID: 28145883
Free PMC article.